Skip to main content
Premium Trial:

Request an Annual Quote

Satoris to Distribute RBM's Biomarker Panel for Neuro Research

NEW YORK (GenomeWeb News) – Molecular diagnostics firm Satoris today said that it has been appointed global distributor for Rules-Based Medicine's DiscoveryMAP panel for neurology research.

The RBM DisocveryMAP is a 189-biomarker panel that covers the most physiologically relevant pathways and includes biomarkers known to be important in the major disease processes for drug development, said Redwood City, Calif.-based Satoris in a statement.

Cris McReynolds, president and CEO of Satoris, said that the RBM panel "will be an important tool in accelerating research on Alzheimer's disease and related neurodegenerative disorders."

Satoris noted that in June it launched three of its own biomarker panels including a Dementia Discrimination panel, which the firm said is used to differentiate Alzheimer's patients from patients with other forms of dementia. It also introduced its Neuro61 and Neuro77 panels to identify plasma proteins associated with neurodegeneration and neuroinflammation.

Financial and other terms of the agreement with Austin, Texas-based RBM were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.